Pasithea Therapeutics Corp. — Investor Relations & Filings
Filings indexed
301
across all filing types
Latest filing
2026-05-15
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
KTTA
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-15 | English | |
| 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-12 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 46363349 | QUARTERLY REPORT | 2026-05-15 | English | ||
| 32899636 | 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | ||
| 32021647 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021493 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 32021479 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021505 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 32021490 | S-8 Filing | 2026-01-30 | English | ||
| 32021563 | 8-K Filing | 2026-01-28 | English | ||
| 13367478 | POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 | 2026-01-26 | English | ||
|
2025
6 filings
| |||||
| 13367481 | DEFINITIVE PROXY STATEMENT | 2025-12-29 | English | ||
| 13367482 | PRELIMINARY PROXY STATEMENT | 2025-12-19 | English | ||
| 13367480 | CURRENT REPORT | 2025-12-15 | English | ||
| 13367483 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367484 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367489 | CURRENT REPORT | 2025-12-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Biovica International B
Develops blood-based biomarker assays for cancer therapy mo…
|
BIOVIC | SE | Professional, scientific and te… |
|
Boji Medical Technology Co., Ltd.
A CRO providing full-service pharmaceutical and medical dev…
|
300404 | CN | Professional, scientific and te… |
|
Bonus BioGroup Ltd.
A clinical-stage biotech firm developing cell therapy and t…
|
BONS | IL | Professional, scientific and te… |
|
BPH GLOBAL LTD
Biotech firm focused on plant-based health products and fun…
|
BP8 | AU | Professional, scientific and te… |
|
BRAIN Biotech AG
Develops enzymes and microorganisms for the food, chemical,…
|
BNN | DE | Professional, scientific and te… |
|
BriaCell Therapeutics Corp.
Clinical-stage immuno-oncology company developing cellular …
|
BCTX | CA | Professional, scientific and te… |
|
Bright Minds Biosciences Inc.
Developing innovative serotonin-based drugs for neurologica…
|
DRUG | CA | Professional, scientific and te… |
|
BRIM
Develops therapies for ophthalmology and degenerative disea…
|
6885 | TW | Professional, scientific and te… |
|
BSF ENTERPRISE PLC
Develops cell-based solutions for cultivated meat, leather,…
|
BSFA | GB | Professional, scientific and te… |
|
BullFrog AI Holdings, Inc.
A technology company applying AI and machine learning to dr…
|
BFRG | US | Professional, scientific and te… |
Pasithea Therapeutics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35389/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35389 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35389 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35389 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35389}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Pasithea Therapeutics Corp. (id: 35389)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.